Caspian Journal of Internal Medicine
Babol University of Medical Sciences
یکشنبه 27 مهر 1404
[Archive]
دوره 16، شماره 4 - ( 6-1404 )
جلد 16 شماره 4 صفحات 766-755 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kareem H A, Ghadi H H. Reshape Memory T Cell Landscape in CML Patients' Blood by Tyrosine Kinase Inhibitors. Caspian J Intern Med 2025; 16 (4) :755-766
URL: http://caspjim.com/article-1-4595-fa.html
URL: http://caspjim.com/article-1-4595-fa.html
Reshape Memory T Cell Landscape in CML Patients' Blood by Tyrosine Kinase Inhibitors. . 1404; 16 (4) :755-766
چکیده: (51 مشاهده)
Background: CML, a blood cancer characterized by excessive myeloid cell proliferation, stems from the BCR-ABL1 gene fusion. This research aimed to uncover why leukemic stem cells resist treatment and explore innovative immune-based therapies to improve patient outcomes.
Methods: This study investigated the immunologic phenotypes (CD8, CD27, CD197, and CD45RA) of T cell subsets (TN, TCM, TEM, and TEF) in the peripheral blood of chronic myeloid leukemia patients in the chronic phase who achieved a complete molecular response to tyrosine kinase inhibitors. The treatment-free remission (TFR) patients were compared to age- and gender-matched healthy volunteers using multicolor flow cytometry for analysis.
Results: Flow cytometry analysis unveiled notable shifts in CD8+ T cell subsets. CML-CP patients showed a marked decrease in central memory T cells (TCM), dropping to 7.2% of the CD8+ population. Conversely, these patients exhibited substantial increases in effector memory T (TEM) and effector T (TEF) cells, rising to 37.6% and 24.4% respectively. The most statistically significant change occurred in the CD8+ TEF subset. CML-CP patients displayed a 24.4% presence of these cells, compared to only 15.7% in control groups. These findings suggest a distinct immunological profile in CML-CP, potentially impacting disease progression and treatment strategies.
Conclusion: Tyrosine kinase inhibitors restore the distribution of memory T cells in patients with chronic myeloid leukemia (CML), but T cell exhaustion remains an issue. This situation highlights the need for alternative activation strategies to enhance immunity.
Methods: This study investigated the immunologic phenotypes (CD8, CD27, CD197, and CD45RA) of T cell subsets (TN, TCM, TEM, and TEF) in the peripheral blood of chronic myeloid leukemia patients in the chronic phase who achieved a complete molecular response to tyrosine kinase inhibitors. The treatment-free remission (TFR) patients were compared to age- and gender-matched healthy volunteers using multicolor flow cytometry for analysis.
Results: Flow cytometry analysis unveiled notable shifts in CD8+ T cell subsets. CML-CP patients showed a marked decrease in central memory T cells (TCM), dropping to 7.2% of the CD8+ population. Conversely, these patients exhibited substantial increases in effector memory T (TEM) and effector T (TEF) cells, rising to 37.6% and 24.4% respectively. The most statistically significant change occurred in the CD8+ TEF subset. CML-CP patients displayed a 24.4% presence of these cells, compared to only 15.7% in control groups. These findings suggest a distinct immunological profile in CML-CP, potentially impacting disease progression and treatment strategies.
Conclusion: Tyrosine kinase inhibitors restore the distribution of memory T cells in patients with chronic myeloid leukemia (CML), but T cell exhaustion remains an issue. This situation highlights the need for alternative activation strategies to enhance immunity.
نوع مطالعه: Original Article |
موضوع مقاله:
Oncology
دریافت: 1403/9/2 | پذیرش: 1403/11/1 | انتشار: 1404/6/27
دریافت: 1403/9/2 | پذیرش: 1403/11/1 | انتشار: 1404/6/27
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
